Introduction

Tenecteplase (TNK-tPA, Metalyse^®)

Tenecteplase, TNK-tPA, is a third-generation fibrinolytic or thrombolytic agent used to dissolve occlusive blood clots (thrombi) that can form in cerebral or coronary blood vessels. It is a fibrin-specific plasminogen activator produced in a Chinese hamster ovary cell line by recombinant DNA technology. Since 2001 Metalyse 40 and 50 mg have been approved in Europe for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms. In January 2024 the EMA approved Metalyse^® 5000 units (25mg) for the treatment of acute ischaemic stroke (AIS) in adult patients within 4.5 hours from last known well, and after and after exclusion of intracranial haemorrhage.¹

This section provides information about Metalyse^® 5000 units (25mg), including the mode of action, instructions for use, and prescribing information.